These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 32820390

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR, Daniels DJ, Portoghese PS, Roerig SC.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):75-82. PubMed ID: 17383633
    [Abstract] [Full Text] [Related]

  • 4. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL, Bartlett JL, Ananthan S, Bilsky EJ.
    J Pharmacol Exp Ther; 2001 May 02; 297(2):597-605. PubMed ID: 11303048
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL, Faunce KE, Rice KC, Obeng S, Zhang Y, Blough BE, Grim TW, Negus SS, Banks ML.
    Neuropharmacology; 2019 May 15; 150():200-209. PubMed ID: 30660628
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW, Folk JE, Linsenmayer DC, Rice KC, Negus SS.
    J Pharmacol Exp Ther; 2003 Dec 15; 307(3):1054-64. PubMed ID: 14557380
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence.
    Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE.
    Pharmacol Res Perspect; 2018 Jul 15; 6(4):e00403. PubMed ID: 29930811
    [Abstract] [Full Text] [Related]

  • 9. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M.
    Brain Res; 2006 Apr 14; 1083(1):61-9. PubMed ID: 16530171
    [Abstract] [Full Text] [Related]

  • 10. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
    Riba P, Friedmann T, Király KP, Al-Khrasani M, Sobor M, Asim MF, Spetea M, Schmidhammer H, Furst S.
    Brain Res Bull; 2010 Jan 15; 81(1):178-84. PubMed ID: 19800397
    [Abstract] [Full Text] [Related]

  • 11. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
    Maguire DR, Yang W, France CP.
    J Pharmacol Exp Ther; 2013 Jun 15; 345(3):354-62. PubMed ID: 23536317
    [Abstract] [Full Text] [Related]

  • 12. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
    Solinas M, Goldberg SR.
    Psychopharmacology (Berl); 2005 Jun 15; 179(4):804-12. PubMed ID: 15619107
    [Abstract] [Full Text] [Related]

  • 13. The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
    Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, Wilkerson JL.
    Psychopharmacology (Berl); 2019 Sep 15; 236(9):2725-2734. PubMed ID: 31098655
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD, Coop A, Matsumoto RR.
    ACS Chem Neurosci; 2013 Sep 18; 4(9):1256-66. PubMed ID: 23713721
    [Abstract] [Full Text] [Related]

  • 15. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN, Walker EA.
    J Pharmacol Exp Ther; 2003 Jan 18; 304(1):301-9. PubMed ID: 12490605
    [Abstract] [Full Text] [Related]

  • 16. Antagonism of delta(2)-opioid receptors by naltrindole-5'-isothiocyanate attenuates heroin self-administration but not antinociception in rats.
    Martin TJ, Kim SA, Cannon DG, Sizemore GM, Bian D, Porreca F, Smith JE.
    J Pharmacol Exp Ther; 2000 Sep 18; 294(3):975-82. PubMed ID: 10945849
    [Abstract] [Full Text] [Related]

  • 17. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
    Abul-Husn NS, Sutak M, Milne B, Jhamandas K.
    Br J Pharmacol; 2007 Jul 18; 151(6):877-87. PubMed ID: 17502848
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antinociceptive effects of opioids following acute and chronic administration of butorphanol: influence of stimulus intensity and relative efficacy at the mu receptor.
    Smith MA, Barrett AC, Picker MJ.
    Psychopharmacology (Berl); 1999 Apr 18; 143(3):261-9. PubMed ID: 10353428
    [Abstract] [Full Text] [Related]

  • 20. Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.
    Minervini V, Lu HY, Padarti J, Osteicoechea DC, France CP.
    Psychopharmacology (Berl); 2018 Aug 18; 235(8):2245-2256. PubMed ID: 29785554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.